^
Association details:
| Biomarker: | EML4-ALK variant 3 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
Published date:
11/20/2021
Excerpt:
...phase 1, dose-escalation and expansion study of ceritinib (fasted) in ALK inhibitor (ALKi)-naïve or ALKi-pretreated patients with locally advanced or metastatic ALK + NSCLC...Of the 71 biopsies with NGS confirmed ALK rearrangement, the most frequently detected rearrangements were EML4-ALK variant 1 (V1) and EML4-ALK V3 (36.6% [26/71] and 32.4% [23/71] respectively)...all patients derived clinical benefit from ceritinib treatment....ceritinib is active against almost all ALK resistance mutations found in ALKi-pretreated patients.
DOI:
10.1016/j.lungcan.2021.11.007
Trial ID:
